Close Menu

Derek Lowe comments on the news that Pfizer's (now discontinued) inhaled insulin (Exubera) had led to an increased chance of lung cancer in clinical trials. Considering the difficulties and risks of drug development, it's hard to guarantee outcome of clinical trials, especially when they should take into account that disease often happens on the order of years, not months. "The truth, as far as I can see, is that no one can guarantee the safety of a new drug.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.